NCT05483491 is a Phase 1 clinical trial of KK-LC-1 TCR-T cells in Gastric Cancer, sponsored by Christian Hinrichs.

Who is sponsoring NCT05483491?

NCT05483491 is sponsored by Christian Hinrichs.

What drugs are being tested in NCT05483491?

Interventions in NCT05483491: KK-LC-1 TCR-T cells, Aldesleukin.

What condition does NCT05483491 study?

NCT05483491 studies Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer.

Is NCT05483491 still recruiting?

NCT05483491 is currently recruiting now. Last updated 30 March 2025.

Last reviewed 2025-03-30 · How we verify

NCT05483491

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Recruiting now Phase 1 Last updated 30 March 2025

What this trial tests

Phase 1 trial testing KK-LC-1 TCR-T cells in Gastric Cancer in 30 participants. Currently enrolling.

Timeline

26 September 2022

Primary endpoint
1 September 2026

31 December 2028

Quick facts

Lead sponsor	Christian Hinrichs
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	26 September 2022
Primary completion	1 September 2026
Estimated completion	31 December 2028
Sites	2 locations across United States

Drugs / interventions tested

KK-LC-1 TCR-T cells — full drug profile →
Aldesleukin (ALDESLEUKIN) — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
Breast Cancer — all drugs for Breast Cancer →
Cervical Cancer — all drugs for Cervical Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

Christian Hinrichs — full company profile →

Who can join

18 and older, any sex, with Gastric Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q, Li J, Zheng H, Yang S, et al · · 2023 · cited 102× · PMID 36750830 · DOI 10.1186/s12943-023-01735-9
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J, Xiao Z, Wang D, Jia L, et al · · 2023 · cited 52× · PMID 37649123 · DOI 10.1186/s12943-023-01844-5
T Cell Based Immunotherapy for Cancer: Approaches and Strategies.
Want MY, Bashir Z, Najar RA. · · 2023 · cited 44× · PMID 37112747 · DOI 10.3390/vaccines11040835
Current and future immunotherapy for breast cancer.
Heater NK, Warrior S, Lu J. · · 2024 · cited 38× · PMID 39722028 · DOI 10.1186/s13045-024-01649-z
Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.
Luo D, Liu Y, Lu Z, Huang L. · · 2025 · cited 31× · PMID 39923010 · DOI 10.1186/s10020-025-01075-y
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
Li R, Cao L. · · 2023 · cited 23× · PMID 37275874 · DOI 10.3389/fimmu.2023.1194020
Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.
Katiyar V, Chesney J, Kloecker G. · · 2023 · cited 19× · PMID 37509394 · DOI 10.3390/cancers15143733

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Christian Hinrichs trials

Trials by the same sponsor.

NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT05686226 — E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483491 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Christian Hinrichs
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483491.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing